Area of research
Immunology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Immunotherapy and Immune Responses, and Cervical Cancer and HPV Research.
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis
In Response to <i>A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis</i>
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).
<i>CXCL9:SPP1</i> macrophage polarity identifies a network of cellular programs that control human cancers
Targeting TBK1 to overcome resistance to cancer immunotherapy
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer
Distinct pattern of <i>TP53</i> mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma
Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines
In-situ tumor vaccination: Bringing the fight to the tumor
Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer
<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence
Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.
PET/CT in the Management of Thyroid Cancers
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Highly prevalent TERT promoter mutations in aggressive thyroid cancers
Human Papillomavirus–related Carcinoma With Adenoid Cystic–like Features
Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients
Human Papillomavirus-related Carcinomas of the Sinonasal Tract